Jupiter Life Line Hospitals Limited IPO Message Board (Page 33)

Sebi Observation letter issued below IPOs last week end on 1-Sep-2023

1. Motisons Jewellers Limited (28-Aug-2023)
2. Samhi Hotels Limited (31-Aug-2023)

I had already Informed about Motisons Jewellers
Samhi was Unexpected

JUPITER 10+ 5000
EMS 10 + 4500
At Rajkot

@pRace yes

JUPITER ₹215-220
RATNAVEER ₹53-55
EMS ₹120-123
VISHNU ₹69-70

price band similar to concord, GMP is also similar to concord....

subscription aur listing bhi similar hoga kya ???

​@pRACE  Concord almost double size ka issue tha jupiter se

कोई GMP तो बताओ

210

yatharth vs jupiter life line which one is better and why.

​@Iamfoolish Jupiter
Reasons: Better expansion and growth plans, Higher ARPOB(Almost double of Yatharth) and better expertise than yatharth etc
Though my preferred pick in Hospital stock are Medanta, Rainbow and Narayana

Off topic:
Does anyone know why there is a rally in Yesbank?
(No, i don't have a position, just curious)

​@newgen consultancy pls give ur views on trident , i am holding it till year 2026 at least

​@Gopala I am Not much Bullish on AEROFLEX , Valuations are now unimaginable
Can Exit om Bounce or Hold fir atleast 6 months for Reasonable Profits

​@Manan Surana Good Structure
Short term Target of 46 and Long term 65

​@newgen consultancy  Sir Latest gmp of all ongoing & upcoming IPOs?

Post-IPO, debt-free status of hospital with specialization in services like neuro-rehabilitation and multi-organ transplantation sets it apart in the healthcare sector.
---APPLY--- (for Investors)

Seems Dilip Davda Sir has corrected the P/E as 52.68 instead of earlier 66 (approx).

So, now, after repayment of whole debt of approx 510 Cr, the revised P/E may come down to a range of almost 41-42.

Pls correct me Sir @Jetha Lal @newgen consultancy  and all other experts. 🙏

​@untamed inferno  yes the fresh issue is raised to pay off the existing debt. For the current year interest will be saved for 6 months.
Which will boost profit and lower down the PE.

If one factors full debt payment interest savings (net taxes) and FY23-24 and FY 24-25 growth in revenue and then calculate profit as a assumed % of revenue, forwards EPS will be very good reducing PE substantially, making it a an attractive bet to buy now. (One should assume the variable in the above as per his assumptions)

Note :- I haven’t still decided whether I’ll apply in sHNI or bHNI from all my 11 accounts. Chances of getting allotment will be good because of big size and even if it gives 5% gains it’ll be good profit.

​@ipo stonks Thank you sir for the clarification. Chances of allotment is better.

Once, I visited Jupiter hospital of Thane to see one of my friends admitted there way back in April or May 2013. At that time, i was impressed with the facilities there and the hassle-free cashless treatment viability 10yrs back. I know, this has nothing to do much with this ipo, but still thought of sharing this.

All can opine whether to apply in this issue or not. Thanks.

IPO are coming at high valuation and still commanding good GMP. Time to be cautious?

I agree, we have to be careful.

​@newgen consultancy @Jetha Lal and everyone , kindly explain how does this bulk deal on same day by same entities work and result in , when they buy and sell the same quantity on just 1-2 rs difference , what's the benefit/ affect/ cause of this???

for example the recent deals in global pet by shreni shares pvt ltd and others too , can someone pls check and tell why and what is that ???
​@SJogi @SSingh @MRavichandran @Noorul

I had question in my mind that how they got so much courage to launch IPO at P/E of 66 and why SBI MF and other institution investors participated at such high valuation in Pre-IPO placement at Rs. 735/share for 123 cr worth of shares which is higher band of IPO price as well.
I tried to find out what these institutional investors able to see what we are missing or unable to see and here what i found.

IPO consists of fresh issue of 542 crs which will be utilised for loan repayment and general corporate purpose in which they have earmarked 510 cr for loan repayment. As per RHP on 30th August they had total o/s loan of Rs. 476 cr which will be completely paid off and this company will be completely debt free. I haven't find out how they are going to fund 500 beds upcoming hospital in Dombivli whose construction began in April 2023. It may be funded through internal accrual or maybe they raise debt in upcoming year. No clarity about this.

So how it impacts future earning and valuation?
In FY 23 they paid finance expenses of Rs 42.27 cr which will be saved and it will increase its profitability in coming year and it will make it b/s lean. In FY 23 they have net profit of Rs 73 cr and if i add finance charges post tax(42.27*75%= ~ 32 cr considering 25% tax rate for tax benefit on interest charges) which boost Net profit around 105 cr for FY 23 which makes P/E ratio around 45 which is still fully valued. Institution may have good hope from improved performance of Indore hospital(431 beds which is 36% of total capacity and contributing mere 12% in total revenue) which was acquired in 2020 whose occupancy was 40% and ARPOB of Rs 38K which is significantly lower than their two other hospitals in Thane & Pune whose occupancy were 72% & 67% respectively and ARPOB of Rs 56K & 49K respectively.

I just made rough calculation and tried to find out how IPO proceed and debt status is going to affect financial and valuation of this company in coming year and how these institution makes decision.

This is not apply or avoid call for this IPO and it is just for learning purpose. I would love to have feedback of respected members.

Thanks.

​@Sleeping lion Ji, GMP is never a key point for applying in a IPO for me. If i followed GMP blindly then i would had missed few wonderful companies for long term growth. If i apply in IPO then my primary focus is to find good quality companies with sound financial and moderate valuation to reap benefit for short to medium term and hold them until it shows growth. Some holding are MTAR Tech, Medanta, Mrs Bector, MapmyIndia, Nazara, Syrma, Cyient DLM, Harsha, Bikaji, EMIL, IKIO, Senco, Archean, Rainbow, Clean, Sansera which i hold from IPO. Few where i booked profit are Campus, Mankind, Kaynes, Aether etc

@Seth. Ji, You are welcome:)

@M R Shah Thanks sir:)

@Hope is life Kaynes is best among ED&M sector company but i sold it in need of money. I keep it on track and will accumulate someday again.

Though i didn't get any allotment and neither i bought post listing but i am happy that i could able to comprehend what Biggies see here.
I am happy for everyone who tried to understand the valuation game, believed in it and made money in it.
Sometimes we need to clean the foggy mirror to see more clearly beyond past numbers.
I am studying hospital sector since Rainbow IPO and following this sector closely and made good money in Medanta and then in Mankind and latest in Concord as per my understanding and observation beyond GMP and valuation based on past numbers.

Learning is a process and if you keep on learning and applying it then money will follow as well.

Once again congratulations everyone :)

Thanks.

CNC Automation Machinery Maker
JYOTI CNC AUTOMATION Ltd. Files DRHP with Market Regulator SEBI

Issue Size : 1000 Cr
( Company can Consider 200 cr as Pre-IPO placement )
Retail : 10%

LM :
1.Equirus Capital
2.ICICI Securities
3.SBI Capital

Registrar :

FY 23 :
Revenue - 929.3 Cr
PAT - 15.06 Cr

Orderbook : 3143 Cr
Clientele : ISRO, BrahMos Aerospace Thiruvananthapuram, Turkish Aerospace, Tata Advances System, Bharat Forge, Shreeram Aerospace & Defence LLP and Bosch
I already knew About This IPO 4 Months Back
Very Excited about this

Silver pumps & motors.

​@Sharvam Okay got it sir, thank you

I had shorted this in the grey market at 190
Lets see loss toh loss profit toh profit

Clear avoid. Asking double premium .not justified

"As per the offer document, JLLHL has shown Apollo Hospitals, Fortis Healthcare, Max Healthcare, Narayana Hrudayalaya, Global Health and Krishna Institute as their listed peers. They are currently trading at a P/E of 71.74, 214.62, 78.27, 70.35, 65.46, and 60.75 (as of September 01, 2023). However, they are not truly comparable on an apple-to-apple basis. "

As per Screener(P/E) :
Fortis - 46.9 Max - 47.7 Narayana- 30.8 Global Health-51.3 Krishna Institute-45.9

This is updated comparison posted by company in RHP.
Post issue PE of Jupiter comes out to be 66 on FY 2023 basis.

GMP collapses to 63-64

Kiska. Jupitar ka

Wait for the anchor book to come before takng any decision..Good peers available at decent valuation..promoters looks greedy here..not expectng grey market to sustain..max 5-7% listing gain possible.